gefitinib has been researched along with Adenocarcinoma, Follicular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clark, JR; Daniels, GH; Evans, T; Fidias, PH; Gurubhagavatula, S; Haddad, RI; Heist, RS; Lynch, TJ; Pennell, NA; Ross, DS; Temel, JS; Wirth, LJ | 1 |
| Aguilera, J; Chang, CY; Lopez, JP; Ongkeko, WM; Pardo, FS; Sneh, G; Wang-Rodriguez, J; Yu, MA | 1 |
1 trial(s) available for gefitinib and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
A phase II study of gefitinib in patients with advanced thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Papillary; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Quinazolines; Severity of Illness Index; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
1 other study(ies) available for gefitinib and Adenocarcinoma, Follicular
| Article | Year |
|---|---|
Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Quinazolines; Thyroid Neoplasms | 2008 |